Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
editorial
. 1996 Feb;73(4):415–417. doi: 10.1038/bjc.1996.73

Aromatase inhibitors--where are we now?

W R Miller 1
PMCID: PMC2074470  PMID: 8595151

Full text

PDF
417

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adi F. C. Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria. Br Med J. 1974 Feb 2;1(5900):183–185. doi: 10.1136/bmj.1.5900.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Demers L. M. Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat. 1994;30(1):95–102. doi: 10.1007/BF00682744. [DOI] [PubMed] [Google Scholar]
  3. Demers L. M., Kleerekoper M. Recent advances in biochemical markers of bone turnover. Clin Chem. 1994 Nov;40(11 Pt 1):1994–1995. [PubMed] [Google Scholar]
  4. Demers L. M., Lipton A., Harvey H. A., Hanagan J., Mulagha M., Santen R. J. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):683–685. doi: 10.1016/0960-0760(93)90282-2. [DOI] [PubMed] [Google Scholar]
  5. Dowsett M., Smithers D., Moore J., Trunet P. F., Coombes R. C., Powles T. J., Rubens R., Smith I. E. Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. Eur J Cancer. 1994;30A(10):1453–1458. doi: 10.1016/0959-8049(94)00281-9. [DOI] [PubMed] [Google Scholar]
  6. Goss P. E., Clark R. M., Ambus U., Weizel H. A., Wadden N. A., Crump M., Walde D., Tye L. M., De Coster R., Bruynseels J. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res. 1995 Mar;1(3):287–294. [PubMed] [Google Scholar]
  7. Hackenberg R., Turgetto I., Filmer A., Schulz K. D. Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells. J Steroid Biochem Mol Biol. 1993 Nov;46(5):597–603. doi: 10.1016/0960-0760(93)90187-2. [DOI] [PubMed] [Google Scholar]
  8. Harris A. L., Dowsett M., Jeffcoate S. L., McKinna J. A., Morgan M., Smith I. E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab. 1982 Oct;55(4):718–722. doi: 10.1210/jcem-55-4-718. [DOI] [PubMed] [Google Scholar]
  9. Johnston S. R., Smith I. E., Doody D., Jacobs S., Robertshaw H., Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 1994 Nov 15;54(22):5875–5881. [PubMed] [Google Scholar]
  10. Lipton A., Demers L. M., Harvey H. A., Kambic K. B., Grossberg H., Brady C., Adlercruetz H., Trunet P. F., Santen R. J. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer. 1995 Apr 15;75(8):2132–2138. doi: 10.1002/1097-0142(19950415)75:8<2132::aid-cncr2820750816>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  11. Lønning P. E. Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemother Pharmacol. 1990;26(4):241–244. doi: 10.1007/BF02897223. [DOI] [PubMed] [Google Scholar]
  12. Masamura S., Adlercreutz H., Harvey H., Lipton A., Demers L. M., Santen R. J., Santner S. J. Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat. 1995;33(1):19–26. doi: 10.1007/BF00666067. [DOI] [PubMed] [Google Scholar]
  13. Miller W. R. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev. 1989 Jun;16(2):83–93. doi: 10.1016/0305-7372(89)90012-1. [DOI] [PubMed] [Google Scholar]
  14. Miller W. R. Endocrine treatment for breast cancers: biological rationale and current progress. J Steroid Biochem Mol Biol. 1990 Nov 30;37(4):467–480. doi: 10.1016/0960-0760(90)90390-7. [DOI] [PubMed] [Google Scholar]
  15. Pérez Carrión R., Alberola Candel V., Calabresi F., Michel R. T., Santos R., Delozier T., Goss P., Mauriac L., Feuilhade F., Freue M. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol. 1994;5 (Suppl 7):S19–S24. [PubMed] [Google Scholar]
  16. Smith I. E., Harris A. L., Morgan M., Ford H. T., Gazet J. C., Harmer C. L., White H., Parsons C. A., Villardo A., Walsh G. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed) 1981 Nov 28;283(6304):1432–1434. doi: 10.1136/bmj.283.6304.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES